Atlas Trials

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Clinical trial NCT04504331 · TERMINATED

Trial details

NCT number
NCT04504331
Sponsor
Jennifer Lee Caswell-Jin
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Breast CancerHER2-negative Breast CancerER Positive Breast CancerPR-Positive Breast Cancer
Start date
2020-10-13
Primary completion
2021-10-22
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.